A meta-analysis of four Nordic countries (23.1 million residents) reveals that, in the 12-15 age group , the incidence of myocarditis after infection was zero or residual. The incidence of myocarditis, pericarditis, or both increased five-fold after the first dose and 14-fold after the second dose of mRNA vaccine (Pfizer or Moderna).
The study “ SARS-CoV-2 Vaccination and Myocarditis in a Nordic Cohort Study of 23 Million Residents ” concluded that the risks of myocarditis after suspected infection (positive test) increases with age. On the contrary, the risks of myocarditis after vaccination are higher in younger people (in this case the study only analysed individuals aged 12 years and older).
As can be seen in the tables below, the incidence of myocarditis after infection is zero (or residual) from 12 to 15 years of age in both boys and girls.
The authors also concluded that overall, the study “revealed an increased risk of myocarditis after a positive result for SARS-CoV-2 infection, and the risk was higher in older age groups, while the risk of myocarditis after vaccination was higher in the younger age groups.”
Myocarditis and pericarditis after vaccination
The incidence of myocarditis, pericarditis or both increased significantly after taking mRNA vaccines (Pfizer and Moderna) compared with the reference value (1 per 100,000).
In this age group we need to exercise some caution, as the authors point out that:
“Our findings in children aged 12 to 15 years were limited to relatively few exposed individuals, because vaccination in this age group has only recently begun in most countries.”
Conclusion
According to data from this study and others, the risks of post-infection and post-vaccination myocarditis are quite different, depending on sex and age group.
The authors’ conclusion is that:
“The risk of myocarditis associated with vaccination against SARS-CoV-2 must be balanced against the benefits of these vaccines.”
Also read the article “Boys aged 16-24 are 20 times more likely to have myocarditis after taking different vaccines”.
